Company intelligence / Profile preview

Arena Media

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Arena Pharmaceuticals was a clinical-stage biopharmaceutical company with a pipeline focused on immuno-inflammatory and cardiovascular indications. Its lead asset, etrasimod, was in late-stage development for multiple immune-mediated conditions. Temanogrel and APD418 were both in Phase 2 trials targeting cardiovascular disorders. The company was acquired by Pfizer in March 2022 for $6.7 billion to enhance Pfizer’s immunology and inflammation portfolio

Therapeutic areas: GastroenterologyDermatologyCardiovascularImmunology
Modalities: Small molecule
Industry: Biotech

Partnerships

Not specified post-acquisition; previously independent.

Beyond the preview

Go deeper on Arena Media.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arena Media.

Explore the full profile